Breaking News Instant updates and real-time market news.

BHVN

Biohaven Pharmaceutical

$33.70

-3.18 (-8.62%)

19:53
11/14/18
11/14
19:53
11/14/18
19:53

Biohaven Pharmaceutical undervalued based on its catalysts, says Piper Jaffray

Piper Jaffray analyst Tyler Van Buren kept his Overweight rating and $65 price target on Biohaven Pharmaceutical, stating that its shares are undervalued in a "catalyst-rich year end". The analyst says the company's rimegepant long-term 52-week safety data is expected to be clean while its Phase 3 orally dissolving tablet version for the program could add a "layer of differentiation". Van Bure further points to the company's Phase 3 trial initiation in migraine prevention with an added opportunity for the "ongoing Phase 2/3 troriluzole Alzheimer's study in the middle of next year".

  • 14

    Nov

  • 14

    Nov

  • 15

    Nov

  • 27

    Nov

BHVN Biohaven Pharmaceutical
$33.70

-3.18 (-8.62%)

11/13/18
LEER
11/13/18
INITIATION
Target $50
LEER
Outperform
Biohaven Pharmaceutical initiated with an Outperform at Leerink
Leerink analyst Marc Goodman started Biohaven Pharmaceutical with an Outperform and $50 price target as he initiates Neuroscience space with a Positive View. The analyst believes the Neuroscience sector is experiencing a "renaissance" as multiple new agents and mechanisms are coming up the pipeline across major therapeutic areas, the number of clinical studies is growing nicely, and the FDA is friendly to innovation in this space, companies are getting smarter about speed-to-market strategies and selecting niche sub-populations to focus on for initial product approvals, payer pushback on usage is much lower than in other categories, and physicians are enthusiastic about new agents. Regarding Biohaven Pharmaceutical, Goodman thinks the migraine space will be a significant market, the branded acute segment is underappreciated, and Biohaven will monetize the strong rimegepant clinical profile either with a "go it alone" strategy or most likely via a commercial partner.
11/12/18
LEER
11/12/18
INITIATION
Target $50
LEER
Outperform
Biohaven Pharmaceutical initiated with an Outperform at Leerink
Leerink Partners analyst Marc Goodman started Biohaven Pharmaceutical with an Outperform rating and $50 price target
11/12/18
OPCO
11/12/18
INITIATION
Target $63
OPCO
Outperform
Biohaven Pharmaceutical initiated with an Outperform at Oppenheimer
Oppenheimer analyst Esther Rajavelu started Biohaven Pharmaceutical with an Outperform rating and $63 price target. The stock offers "multiple value drivers" that are not reflected at current trading levels, Rajavelu tells investors in a research note. The analyst believes Biohaven's glutamate platform with two late stage assets is "under-the-radar."
10/24/18
PIPR
10/24/18
NO CHANGE
Target $65
PIPR
Overweight
Piper has 'even greater conviction' in $65 target for Biohaven Pharmaceutical
Piper Jaffray analyst Tyler Van Buren says he left recent meetings with management with "even greater conviction" in his Overweight rating and $65 price target on Biohaven Pharmaceutical. By the end of the year, the analyst expects to receive three important updates: the topline 12-month rimegepant safety data, the initiation of a pivotal rimegepant program for the prevention of migraines and the topline Phase III Zydis orally dissolving tablet data. Following these near-term updates, investors will more appropriately value Biohaven's lead acute migraine treatment opportunity, consider the "fast-following" larger migraine prevention opportunity, and begin to contemplate the other pipeline assets entering late-stage clinical development, Van Buren tells investors in a research note. He believes the company's acute migraine opportunity is still being underappreciated at current valuation levels.

TODAY'S FREE FLY STORIES

10:20
08/21/19
08/21
10:20
08/21/19
10:20
General news
The U.S. July existing home sales report beat estimates »

The U.S. July existing…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
08/21/19
08/21
10:17
08/21/19
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BOOM

DMC Global

$42.78

1.375 (3.32%)

10:17
08/21/19
08/21
10:17
08/21/19
10:17
Conference/Events
DMC Global management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

  • 13

    Nov

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
08/21/19
08/21
10:16
08/21/19
10:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AFL

Aflac

$49.57

-2.29 (-4.42%)

10:15
08/21/19
08/21
10:15
08/21/19
10:15
Options
AFLAC put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
08/21/19
08/21
10:15
08/21/19
10:15
General news
Breaking General news story  »

Week of 8/16 EIA…

HSGX

Histogenics

$0.22

0.0005 (0.23%)

10:14
08/21/19
08/21
10:14
08/21/19
10:14
Hot Stocks
Histogenics merger partner Ocugen granted FDA orphan designation »

Ocugen's treatment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYCN

Cyclerion Therapeutics

$9.59

0.8 (9.10%)

10:12
08/21/19
08/21
10:12
08/21/19
10:12
Upgrade
Cyclerion Therapeutics rating change  »

Cyclerion Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AFL

Aflac

$49.65

-2.21 (-4.26%)

10:11
08/21/19
08/21
10:11
08/21/19
10:11
Recommendations
Aflac analyst commentary  »

Aflac third sector sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLFD

Clearfield

$10.98

(0.00%)

, WSG

Wanda Sports

$4.12

0.22 (5.64%)

10:10
08/21/19
08/21
10:10
08/21/19
10:10
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

CLFD

Clearfield

$10.98

(0.00%)

WSG

Wanda Sports

$4.12

0.22 (5.64%)

INMB

INmune Bio

$6.30

0.46 (7.88%)

CLGX

CoreLogic

$47.28

0.49 (1.05%)

HUBB

Hubbell

$127.70

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 05

    Sep

  • 12

    Sep

  • 13

    Nov

CREE

Cree

$52.88

-5.31 (-9.13%)

, HA

Hawaiian Holdings

$23.94

-1.5 (-5.90%)

10:10
08/21/19
08/21
10:10
08/21/19
10:10
Downgrade
Fly Intel: Top five analyst downgrades »

Catch up on today's…

CREE

Cree

$52.88

-5.31 (-9.13%)

HA

Hawaiian Holdings

$23.94

-1.5 (-5.90%)

CIM

Chimera

$19.52

-0.17 (-0.86%)

SYBX

Synlogic

$3.25

-0.22 (-6.34%)

JAZZ

Jazz Pharmaceuticals

$134.12

-2.42 (-1.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 04

    Sep

  • 05

    Sep

  • 09

    Sep

  • 30

    Oct

NOW

ServiceNow

$263.94

8.44 (3.30%)

, EEX

Emerald Expositions Events

$9.73

0.24 (2.53%)

10:10
08/21/19
08/21
10:10
08/21/19
10:10
Upgrade
Fly Intel: Top five analyst upgrades »

Catch up on today's…

NOW

ServiceNow

$263.94

8.44 (3.30%)

EEX

Emerald Expositions Events

$9.73

0.24 (2.53%)

PSA

Public Storage

$261.11

0.66 (0.25%)

LSI

Life Storage

$104.00

0.68 (0.66%)

ONDK

On Deck Capital

$3.26

0.025 (0.77%)

RDFN

Redfin

$18.28

0.83 (4.76%)

RMAX

RE/MAX Holdings

$27.38

0.71 (2.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 28

    Aug

  • 18

    Sep

  • 27

    Oct

  • 13

    Nov

  • 12

    Dec

  • 16

    Dec

10:10
08/21/19
08/21
10:10
08/21/19
10:10
General news
FX Action: The dollar »

FX Action: The dollar…

10:10
08/21/19
08/21
10:10
08/21/19
10:10
General news
U.S. July existing home sales rebounded 2.5% to 5.420 M »

U.S. July existing home…

PFE

Pfizer

$34.96

0.34 (0.98%)

10:03
08/21/19
08/21
10:03
08/21/19
10:03
Hot Stocks
Pfizer announces additional half billion dollar investment for Sanford facility »

Pfizer announced an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 16

    Sep

LKSD

LSC Communications

$1.34

0.01 (0.75%)

10:03
08/21/19
08/21
10:03
08/21/19
10:03
Hot Stocks
UBM acquires commingle operations from LSC Communications for $11.25M in cash »

LSC Communications and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:02
08/21/19
08/21
10:02
08/21/19
10:02
General news
Existing Home Sales data reported »

July Existing Home Sales…

HURN

Huron

$60.80

(0.00%)

10:02
08/21/19
08/21
10:02
08/21/19
10:02
Conference/Events
Huron management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 29

    Aug

  • 10

    Sep

  • 11

    Sep

  • 17

    Sep

  • 18

    Sep

HURN

Huron

$60.80

(0.00%)

10:01
08/21/19
08/21
10:01
08/21/19
10:01
Conference/Events
Huron management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 29

    Aug

  • 10

    Sep

  • 11

    Sep

  • 17

    Sep

  • 18

    Sep

SPY

SPDR S&P 500 ETF Trust

$292.80

2.77 (0.96%)

, SPX

S&P 500

$0.00

(0.00%)

10:01
08/21/19
08/21
10:01
08/21/19
10:01
General news
Trump tweets about German bonds, asks 'Where is the Federal Reserve?' »

President Donald Trump…

SPY

SPDR S&P 500 ETF Trust

$292.80

2.77 (0.96%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

$107.98

9.94 (10.14%)

10:00
08/21/19
08/21
10:00
08/21/19
10:00
Hot Stocks
Lowe's says seeing increased Pro customer service scores »

Says: Has laundry list of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 25

    Sep

TSLA

Tesla

$222.22

-3.48 (-1.54%)

10:00
08/21/19
08/21
10:00
08/21/19
10:00
Options
Tesla bear spends $318K on Oct downside »

Tesla bear spends $318K…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 23

    Sep

09:57
08/21/19
08/21
09:57
08/21/19
09:57
Conference/Events
The Food & Drug Law Institute to hold a webinar »

Anthony Anscombe, Partner…

GLD

SPDR Gold Shares

$141.65

-0.56 (-0.39%)

09:56
08/21/19
08/21
09:56
08/21/19
09:56
Options
Upside call Seller in SPDR Gold Trust »

Upside call Seller in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$99.51

13.935 (16.28%)

, LOW

Lowe's

$109.03

10.985 (11.20%)

09:55
08/21/19
08/21
09:55
08/21/19
09:55
Options
Early notable gainers among liquid option names on August 21st »

Notable gainers among…

TGT

Target

$99.51

13.935 (16.28%)

LOW

Lowe's

$109.03

10.985 (11.20%)

BBBY

Bed Bath & Beyond

$8.06

0.32 (4.13%)

URBN

Urban Outfitters

$21.97

1.04 (4.97%)

PCG

PG&E

$11.67

0.04 (0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 21

    Aug

  • 22

    Aug

  • 15

    Sep

  • 19

    Sep

  • 25

    Sep

  • 11

    Nov

  • 19

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.